Cypros bolsters its low cash burn strategy

Cypros bolsters its low cash burn strategy Although a number of biotech companies have brought multiple products into advanced clinical trials, few have accomplished the mission by spending less than Cypros Pharmaceutical Corp.

Since inception in November 1990, the Carlsbad, Calif., company has spent $7.5 million while moving its two small molecule drugs into five Phase II trials. ...